MMCB has started testing a new drug for Hemophilia on mice

MMCB has successfully completed in vitro (in vitro) laboratory tests of a range of new gene therapy drugs for the treatment of hemophilia A and B. Now the company's specialists have launched a testing phase on mice in order to determine the minimum effective dose of the drug. The hemophilia therapy market remains one of the largest segments of orphan diseases. By the end of 2025, the volume of sales of drugs for the treatment of hemophilia A in Russia is estimated at about 27.2 billion rubles, and about 1.4 billion rubles for hemophilia B.